Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Revolax is a family of cross-linked hyaluronic acid (HA) dermal fillers developed and manufactured by the South Korean company Across. It is designed for aesthetic soft-tissue augmentation, including the correction of facial wrinkles, lip enhancement, and facial contouring. The filler is composed of high-purity, non-animal-based hyaluronic acid and features a monophasic structure with a dense lattice, which provides consistent injection pressure and enhanced durability within the tissue. Revolax is available in several formulations—Fine, Deep, and Sub-Q—which differ in their viscoelastic properties and are tailored for specific injection depths and treatment areas. While often distributed by e-commerce platforms like CelestaPro, the product is a globally recognized medical aesthetic injectable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Revolax.